brain tumors prevented 100% with shrna in mice, page-11

Glioblastoma is a great therapeutic target for shRNAi. It is one of the most feared cancers in the medical community, and although surgery is usually attempted, all treatment is almost inevitably futile. The challenges of treating this seem insurmountable...until ddRNAi. If one person could be cured of this, it would certainly be a major news story all over the world and would really rocket ddRNAi technology into the spotlight of the public and the investment community.

I did a search in the PubMed database
"shRNA glioblastoma in-vivo" and came up with 111 articles. Naturally, young budding scientists all over the world would think that it would be ultra-cool to do research to help defeat one of the nastiest and difficult to treat cancers around, and so they have. Not all these articles involve ddRNAi as a therapeutic, however it is an indication of another area where Benitec can take advantage of previous research and leapfrog very quickly into clinical trials, again where the human need is so great that red tape and delays will be much less.

A great target for when the licencing deals are rolling in and Benitec is flush with cash to finance the next phase of Benitec's development as a mega ddRNAi therapeutic powerhouse.

A bit of trivia; glioblastoma is approximately 10 times more common than acromegaly! and obviously, much more nasty.